Biotech News
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 response Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027 Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct.
